These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24404903)

  • 1. Is uremic cardiomyopathy a direct consequence of chronic kidney disease?
    Chinnappa S; Hothi SS; Tan LB
    Expert Rev Cardiovasc Ther; 2014 Feb; 12(2):127-30. PubMed ID: 24404903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiac magnetic resonance and uremic cardiomyopathy].
    Di Lullo L; Gorini A; Rivera R; De Pascalis A; Bellasi A; Russo D; Barbera V; Ronco C; Balducci A; Santoboni A
    G Ital Nefrol; 2014; 31(6):. PubMed ID: 25504164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiac manifestations of terminal kidney insufficiency. Current characterization of uremic cardiomyopathy].
    Josephs W; Odenthal HJ
    Dtsch Med Wochenschr; 1995 Feb; 120(5):141-4. PubMed ID: 7843032
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of renal transplantation on uremic cardiomyopathy.
    Parfrey PS; Harnett JD; Foley RN; Kent GM; Murray DC; Barre PE; Guttmann RD
    Transplantation; 1995 Nov; 60(9):908-14. PubMed ID: 7491692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficiency of Soluble α-Klotho as an Independent Cause of Uremic Cardiomyopathy.
    Xie J; Wu YL; Huang CL
    Vitam Horm; 2016; 101():311-30. PubMed ID: 27125747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy.
    Wang X; Chaudhry MA; Nie Y; Xie Z; Shapiro JI; Liu J
    J Vis Exp; 2017 Nov; (129):. PubMed ID: 29155790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expressions of macrophage migration inhibitory factor in patients with chronic kidney disease.
    Liu Y; Zhang X; Liu G; Huang J; Pan Y; Hu Z
    Niger J Clin Pract; 2016; 19(6):778-783. PubMed ID: 27811451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors associated with change rates of LV hypertrophy and renal dysfunction in CKD patients.
    Okumura K; Io H; Matsumoto M; Seto T; Takagi M; Masuda A; Furukawa M; Nagahama L; Omote K; Hisada A; Hamada C; Horikoshi S; Tomino Y
    Clin Nephrol; 2013 Jan; 79(1):7-14. PubMed ID: 23036229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy.
    Kovács ZZA; Szűcs G; Freiwan M; Kovács MG; Márványkövi FM; Dinh H; Siska A; Farkas K; Kovács F; Kriston A; Horváth P; Kővári B; Cserni BG; Cserni G; Földesi I; Csont T; Sárközy M
    Sci Rep; 2021 Sep; 11(1):17495. PubMed ID: 34471171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations.
    Law JP; Pickup L; Pavlovic D; Townend JN; Ferro CJ
    J Hum Hypertens; 2023 Jan; 37(1):1-19. PubMed ID: 36138105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of echocardiographic data in patients with chronic kidney disease.
    Dubin RF
    Curr Opin Nephrol Hypertens; 2018 Jul; 27(4):283-288. PubMed ID: 29781842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management.
    Curtis BM; Parfrey PS
    Cardiol Clin; 2005 Aug; 23(3):275-84. PubMed ID: 16084277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uremic cardiomyopathy: an underdiagnosed disease.
    Alhaj E; Alhaj N; Rahman I; Niazi TO; Berkowitz R; Klapholz M
    Congest Heart Fail; 2013; 19(4):E40-5. PubMed ID: 23615021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Uremic cardiomyopathy in chronic renal insufficiency].
    Ostapiuk FE; Avtandilov AG
    Sov Med; 1983; (11):86-8. PubMed ID: 6658587
    [No Abstract]   [Full Text] [Related]  

  • 15. Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance.
    Edwards NC; Moody WE; Chue CD; Ferro CJ; Townend JN; Steeds RP
    JACC Cardiovasc Imaging; 2014 Jul; 7(7):703-14. PubMed ID: 25034920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease: Managing Volume Overload.
    Zoccali C; Mallamaci F
    Clin J Am Soc Nephrol; 2018 Sep; 13(9):1432-1434. PubMed ID: 30111588
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients.
    Horio T; Iwashima Y; Kamide K; Tokudome T; Yoshihara F; Nakamura S; Kawano Y
    J Hypertens; 2010 Aug; 28(8):1738-44. PubMed ID: 20485194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-oxidative priming but maintained cardiac function in a broad spectrum of murine models of chronic kidney disease.
    Wollenhaupt J; Frisch J; Harlacher E; Wong DWL; Jin H; Schulte C; Vondenhoff S; Moellmann J; Klinkhammer BM; Zhang L; Baleanu-Curaj A; Liehn EA; Speer T; Kazakov A; Werner C; van der Vorst EPC; Selejan SR; Hohl M; Böhm M; Kramann R; Biessen EAL; Lehrke M; Marx N; Jankowski J; Maack C; Boor P; Prates Roma L; Noels H
    Redox Biol; 2022 Oct; 56():102459. PubMed ID: 36099852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrocardiographic abnormalities among dialysis naïve chronic kidney disease patients in Ilorin Nigeria.
    Chijioke A; Makusidi AM; Kolo PM
    Ann Afr Med; 2012; 11(1):21-6. PubMed ID: 22199043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia.
    Berweck S; Hennig L; Sternberg C; Dingerkus H; Ludat K; Hampl H
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S80-5. PubMed ID: 10746811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.